A. Sanyal

Epidemiology · 2001–2023

A researcher in the Science corpus: 32 papers; trusts 9 researchers and is trusted by 16 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 387 citations into it; #174 of 2,148 by trust here, #23 by citations
• Endocrinology, Diabetes and Metabolism — 237 citations into it; #96 of 623 by trust here, #50 by citations
• Hepatology — 213 citations into it; #21 of 151 by trust here, #3 by citations
• Pathology and Forensic Medicine — 68 citations into it; #184 of 414 by trust here, #42 by citations

Whom A. Sanyal trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. Z. Younossi

Who trusts A. Sanyal overall

1. Z. Younossi
2. Q. Anstee
3. N. Chalasani
4. Herbert Tilg
5. S. Friedman
6. M. Rinella
7. V. Ratziu
8. B. Neuschwander‐Tetri
9. G. Targher
10. V. Samuel

Papers from A. Sanyal's perspective

Ordered by how strongly the researchers A. Sanyal trusts endorse each paper. Same corpus, a different order for every researcher.

1. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. (Gastroenterology)
2. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes (Hepatology)
3. ENDPOINTS AND CLINICAL TRIAL DESIGN FOR NONALCOHOLIC STEATOHEPATITIS (Hepatology)
4. Liver Fibrosis, but no Other Histologic Features, Associates with Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease (Gastroenterology)
5. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the… (American Journal of Gastroenterology)
6. Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity (Hepatology)
7. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (Hepatology)
8. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. (Gastroenterology)
9. Meta‐analysis of the influence of I148M variant of patatin‐like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease (Hepatology)
10. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. (Gastroenterology)

Their papers

• The Cirrhosis Dysbiosis Ratio defines Changes in the Gut Microbiome Associated with Cirrhosis and its Complications (2013) — 993 citations
• The Plasma Lipidomic Signature of Nonalcoholic Steatohepatitis (2009) — 663 citations
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature (2023) — 2,276 citations
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature. (2023) — 2,621 citations
• Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease (2021) — 821 citations
• MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease. (2020) — 2,705 citations
• Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. (2020) — 1,115 citations
• A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. (2020) — 1,488 citations
• Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. (2019) — 1,024 citations
• Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. (2018) — 1,677 citations
• Mechanisms of NAFLD development and therapeutic strategies (2018) — 3,682 citations
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018) — 6,253 citations
• Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease (2017) — 2,091 citations
• Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. (2016) — 918 citations
• Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. (2014) — 865 citations
• Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial (2014) — 2,063 citations
• The global NAFLD epidemic (2013) — 1,687 citations
• Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013) — 875 citations
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association (2012) — 2,216 citations
• INCREASED HEPATIC SYNTHESIS AND DYSREGULATION OF CHOLESTEROL METABOLISM IS ASSOCIATED WITH THE SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE (2012) — 631 citations